How do you treat patients with stage III squamous cell carcinoma of the lung with persistent/progressive disease despite concurrent chemoradiation?
How would you utilize PD-L1 expression to guide your decision making in this situation?
Community PollStarted
How do you treat patients with stage III NSCLC with PDL-1 >50% and progressive disease immediately after concurrent chemoradiation with carbo/taxol?
36 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Pittsburgh
Answered on
In patients with persistent disease without true radiographic progression outside the radiation fields, proceeding with consolidation durvalumab per the PACIFIC trial is reasonable. The robust benefits of durvalumab in the PACIFIC trial were likely from treatment of both persistent and micrometastat...
Join for free or sign in to see the full answer